Q2 2025 13F Holders as of 6/30/2025
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
54.6M
-
Number of holders
-
60
-
Total 13F shares, excl. options
-
29.1M
-
Shares change
-
-5.73M
-
Total reported value, excl. options
-
$12.6M
-
Value change
-
-$2.79M
-
Put/Call ratio
-
0.22
-
Number of buys
-
18
-
Number of sells
-
-64
-
Price
-
$0.42
Significant Holders of ALX ONCOLOGY HOLDINGS INC - Common Stock, par value $0.001 per share (ALXO) as of Q2 2025
96 filings reported holding ALXO - ALX ONCOLOGY HOLDINGS INC - Common Stock, par value $0.001 per share as of Q2 2025.
ALX ONCOLOGY HOLDINGS INC - Common Stock, par value $0.001 per share (ALXO) has 60 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 29.1M shares
of 54.6M outstanding shares and own 53.24% of the company stock.
Largest 10 shareholders include venBio Partners LLC (9.7M shares), Redmile Group, LLC (3.39M shares), TANG CAPITAL MANAGEMENT LLC (3.16M shares), Almitas Capital LLC (2.54M shares), VANGUARD GROUP INC (1.6M shares), ACADIAN ASSET MANAGEMENT LLC (1.27M shares), BANK OF AMERICA CORP /DE/ (1.04M shares), BlackRock, Inc. (716K shares), TWO SIGMA ADVISERS, LP (703K shares), and BANK OF MONTREAL /CAN/ (669K shares).
This table shows the top 60 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.